The investigators seek to determine whether Virco®TYPE HIV-1 provides benefits equivalent to those provided by local expert review. The investigators propose that clinic patients of the Ruth M. Rothstein CORE Center who are having genotypic testing performed will be randomized in a 1:1 fashion to local expert review and to Virco®TYPE HIV-1. Results of either method will be shared with primary HIV care providers. Patient outcomes will be reviewed at a time point equal to or greater than 2 months and 6 months following the change in antiretroviral medications following the testing
Patients having some documented genotypic HIV resistance but having more than one fully active medication will be randomized to either local review or algorithmic review by VircoType HIV-1.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
756
VircoType HIV-1 genotypic interpretation
Local Expert Review of HIV Genotypic resistance testing
The Ruth M. Rothstein CORE Center
Chicago, Illinois, United States
RECRUITINGProportion of patients with viral load <1000 60days after HIV regimen change
Time frame: 60 days
Proportion of patients with viral load <1000 180 days after HIV regimen change
Time frame: 180 days
Proportion of patients with undetectable viral load 60days after HIV regimen change
Time frame: 60 days
Proportion of patients with undetectable viral load 180days after HIV regimen change
Time frame: 180 days
CD4 Cell count change in each arm at 60 and 180 days
Time frame: 60 and 180 days
Proportion of patients whose regimen fails and who require repeat resistance testing at 180 and 360 days
Time frame: 180 and 360 days
Comparison of number of active drugs predicted by each review method and number of actual active drugs prescribed
Time frame: 180 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.